Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System

Executive Summary

As more generic applications arrive, Office of Generic Drugs staff may have a tougher time reaching review goals.

You may also be interested in...

US FDA Might Be Temporarily Headed By Ostroff As Califf Sets His Departure

Former acting commissioner in line for the temporary position again under FDA policy, unless incoming Trump administration designates someone else.

Generic Application Quality Showing Signs Of Improvement

US FDA’s monthly refuse-to-receive numbers for ANDAs are down early in FY 2017, suggesting that sponsor have an increased understanding of the agency’s standards.

ANDA Submission Wave Continues; Is A Crest Near?

Sponsors continue to submit generic drug applications at elevated rate for second-straight month as approvals increase.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts